Carl Voegtlin

Carl Voegtlin
Born(1879-07-28)July 28, 1879
Zofingen, Switzerland
DiedApril 9, 1960(1960-04-09) (aged 80)
Washington, D.C., US[1]
Occupation(s)pharmacologist, organic chemist
Academic background
EducationUniversity of Basel
University of Munich
University of Freiburg
Doctoral advisorLudwig Gattermann
Academic work
InstitutionsUniversity of Wisconsin–Madison
Johns Hopkins University
United States Public Health Service
National Cancer Institute

Carl Voegtlin (July 28, 1879 – April 9, 1960), also Karl Voegtlin, was a Swiss-American pharmacologist, organic chemist, and the first director of the U.S. National Cancer Institute.[2] He is known for his research into the biochemical effects of cancer,[3] contributions to the pharmacology of arsenicals[4][5] and the discovery, with Homer Smith, of mapharsen as the active agent in Paul Ehrlich's Salvarsan.[1][6][7][8][9]

  1. ^ a b "Carl Voegtlin—Obituary and Bibliography". JNCI: Journal of the National Cancer Institute. 25 (4): III–XV. 1 October 1960. doi:10.1093/jnci/25.4.III.
  2. ^ "Dr. Carl Voegtlin". Nature. 152 (3853): 271. 1943. Bibcode:1943Natur.152Q.271.. doi:10.1038/152271a0.
  3. ^ "Trends in Cancer Research1". JNCI: Journal of the National Cancer Institute. 1942. doi:10.1093/jnci/2.4.309. ISSN 1460-2105.
  4. ^ Parascandola, John (1977). "Carl Voegtlin and the 'Arsenic Receptor' in Chemotherapy". Journal of the History of Medicine and Allied Sciences. XXXII (2): 151–171. doi:10.1093/jhmas/XXXII.2.151. ISSN 0022-5045.
  5. ^ Hughes, Michael F.; Beck, Barbara D.; Chen, Yu; Lewis, Ari S.; Thomas, David J. (2011). "Arsenic Exposure and Toxicology: A Historical Perspective". Toxicological Sciences. 123 (2): 305–332. doi:10.1093/toxsci/kfr184. ISSN 1096-6080. PMC 3179678. PMID 21750349.
  6. ^ "DR. CARL VOEGTLIN DIES; First Head of the National Cancer Institute Was 80". The New York Times. 11 April 1960.
  7. ^ Cite error: The named reference historia was invoked but never defined (see the help page).
  8. ^ Voegtlin, Carl (1925). "The Pharmacology of Arsphenamine (Salvarsan) and Related Arsenicals". Physiological Reviews. 5 (1): 63–94. doi:10.1152/physrev.1925.5.1.63. ISSN 0031-9333.
  9. ^ Lloyd, Nicholas C.; Morgan, Hugh W.; Nicholson, Brian K.; Ronimus, Ron S. (2005-01-28). "The Composition of Ehrlich's Salvarsan: Resolution of a Century-Old Debate". Angewandte Chemie International Edition. 44 (6): 941–944. doi:10.1002/anie.200461471. hdl:10289/207. ISSN 1433-7851.